Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A [1 ]
Lisak, L [1 ]
Dutt, D [1 ]
Dean, L [1 ]
Fantroy, L [1 ]
Syed, E [1 ]
Gezer, S [1 ]
Hsu, WT [1 ]
Goldberg, C [1 ]
Loew, J [1 ]
Venugopal, P [1 ]
机构：
[1] Rush Univ, MDS Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4830
引用
收藏
页码：273B / 273B
页数：1
相关论文
共 50 条
  • [41] Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)
    Al-Issa, Karam
    Madanat, Yazan F.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Gerds, Aaron T.
    Abuhadra, Nour
    Makhoul, Ahed
    Awada, Hassan
    Asad, Mohammad Fahad B.
    Goyal, Abhinav
    Advani, Anjali S.
    Kuzmanovic, Teodora
    Przychodzen, Bartlomiej P.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    Nazha, Aziz
    BLOOD, 2017, 130
  • [42] Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases
    Komrokji, Rami S.
    Kulasekararaj, Austin G.
    Al Ali, Najla H.
    Kordasti, Shahram Y.
    Bart-smith, Emily
    Benjamin, Craig
    Padron, Eric
    Zhang, Ling
    Lancet, Jeffrey E.
    List, Alan
    Mufti, Ghulam J.
    Epling-Burnette, Pearlie K.
    BLOOD, 2013, 122 (21)
  • [43] Treatment and outcome of 23 paediatric patients with myelodysplastic syndromes (MDS)
    Polychronopoulou, S
    Panagiotou, JP
    Papadakis, V
    Parcharidou, A
    Psiachou, H
    Mavrou, A
    Haidas, S
    LEUKEMIA, 2000, 14 (05) : 969 - 969
  • [44] Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
    Zemanova, Zuzana
    Michalova, Kyra
    Brezinova, Jana
    Lhotska, Halka
    Svobodova, Karla
    Sarova, Iveta
    Lizcova, Libuse
    Izakova, Silvia
    Ransdorfova, Sarka
    Krejcik, Zdenek
    Belickova, Monika
    Siskova, Magda
    Jonasova, Anna
    Neuwirtova, Radana
    Zmolikova, Jana
    Cermak, Jaroslav
    BLOOD, 2014, 124 (21)
  • [45] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
    List, AF
    Holmes, H
    Greenberg, PL
    Bennett, JM
    Oster, W
    BLOOD, 1999, 94 (10) : 305A - 305A
  • [46] Clinical Experience of Decitabine in Elderly Patients with Myelodysplastic Syndromes (MDS)
    Geils, George F., Jr.
    BLOOD, 2009, 114 (22) : 1092 - 1092
  • [47] THE IMPACT OF MYELODYSPLASTIC SYNDROMES (MDS) ON THE MENTAL HEALTH OF PATIENTS AND CAREGIVERS
    Scheurmeyer, Isabel
    Hughes, Mary
    Sloan, Erika
    LeBlanc, Thomas
    Houk, Alice
    Sirewu, Nyaradzo
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [48] Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS.
    Dourado, CMC
    Seixas-Silva, JA
    Besa, EC
    BLOOD, 2000, 96 (11) : 260B - 260B
  • [49] Diagnostic procedures and treatment of patients with Myelodysplastic Syndromes (MDS) - update of the outpatient MDS registry
    Schmitz, S.
    Boettger, I
    Sauer, A.
    Buschmann, D.
    Germing, U.
    Severin, K.
    Steinmetz, H. T.
    ONKOLOGIE, 2013, 36 : 242 - 242
  • [50] Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis.
    Mingrone, W
    Alietti, A
    Ferrucci, F
    Cocorocchio, E
    Peccatori, F
    Cinieri, S
    Corsini, C
    Zucca, E
    Bertolini, F
    Martinelli, G
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
12345